RBC Europe’s Juno Therapeutics, Inc. JUNO Stock Holding History

RBC Europe’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-400	Closed	-$17.9K	–	1171
2017 Q3	$17.9K	Buy	+400	New	+$13.6K	﹤0.01%	707

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

RBC Europe's JUNO Position: Q4 2017 in Review

RBC Europe sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 400 shares — an estimated $17.9K sold.

RBC Europe first reported a position in JUNO in Q3 2017 and held it in 1 quarter. The position peaked at $17.9K in Q3 2017. 237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

RBC Europe reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
RBC Europe sold 400 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $17.9K.
RBC Europe first reported a position in Juno Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
RBC Europe's Juno Therapeutics, Inc. position peaked at $17.9K in Q3 2017.
237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on RBC Europe's 13F filing for Q4 2017, filed 9 Nov 2023.